Cost Consequences and Health Outcomes of Emtricitabine and Tenofovir Alafenamide (FTC/TAF), a Novel Two-drug Fixed-dose Combination for HIV Patients

F. Altice, E. DeJesus

Yale University School of Medicine, New Haven, CT; Orlando Immunology Center, Orlando, FL

Objectives

To estimate the health outcomes and resource consequences associated with FTC/TAF-based MTRs in the treatment-naive (TN) and treatment-experienced (TE) populations.

Methods: Model Structure

A 2-state Markov model with 52 cycles, each representing an individual’s 1-year health state and cost experience.

Methods: Health Outcomes Analyses and Data Sources

For each type of comorbid event (CKD-H, CVD, and MOF), patients were classified into baseline patient groups (high, medium, and low risk).

Methods: Costs and Data Sources

Costs were calculated for the entire patient population and in an unadjusted (as is) and adjusted (as is + covariates panel) manner. Costs included both drug and nondrug components.

Results

Don’t miss this important poster presentation at IDWeek™; October 26-30, 2016; New Orleans, Louisiana.

Acknowledgments and Disclosures

Funding for this study was provided by Bristol-Myers Squibb, Inc. Medical writing and manuscript support was provided by Fondi 2, Inc. Bristol-Myers Squibb and Fondi 2, Inc. were funded by Bristol-Myers Squibb, Inc.

References


Poster presented at IDWeek™; October 26-30, 2016; New Orleans, Louisiana.